A61K 31/203
Retinoic acids
Official title: Retinoic acids {; Salts thereof}
A61K31/203 (Retinoic acids) appears on 514 US grants and 1,039 published applications in this corpus.
Search patents in A61K- Granted patents
- 514
- Published applications
- 1,039
- Assignees
- 499
- Inventors
- 1,774
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 8 | 0 |
| 1998 | 13 | 0 |
| 1999 | 17 | 0 |
| 2000 | 8 | 0 |
| 2001 | 11 | 2 |
| 2002 | 7 | 29 |
| 2003 | 16 | 37 |
| 2004 | 10 | 27 |
| 2005 | 4 | 47 |
| 2006 | 9 | 56 |
| 2007 | 7 | 36 |
| 2008 | 6 | 32 |
| 2009 | 8 | 45 |
| 2010 | 14 | 40 |
| 2011 | 14 | 36 |
| 2012 | 13 | 34 |
| 2013 | 17 | 42 |
| 2014 | 23 | 46 |
| 2015 | 21 | 38 |
| 2016 | 18 | 47 |
| 2017 | 21 | 53 |
| 2018 | 29 | 40 |
| 2019 | 27 | 57 |
| 2020 | 36 | 53 |
| 2021 | 30 | 52 |
| 2022 | 25 | 45 |
| 2023 | 22 | 39 |
| 2024 | 30 | 41 |
| 2025 | 25 | 40 |
| 2026 | 20 | 25 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions comprising HDAC inhibitors and retinoids22 Sep 2026US 12,740,953 B2The Regents of the University of California
- Inhibitors of the peptidyl-prolyl cis/trans isomerase (PIN1), combinations and uses thereof8 Sep 2026US 12,728,132 B2Beth Israel Deaconess Medical Center, Inc.
- Edible plant exosome-like nanovectors for vaccination11 Aug 2026US 12,702,703 B2University of Louisville Research Foundation, Inc.
- Retinoic acid precursor and anticancer drug composition comprising same30 Jun 2026US 12,667,580 B2Industrial Cooperation Foundation Jeonbuk National University
- Compositions and methods for treating chronic myelomonocytic leukemia30 Jun 2026US 12,668,797 B2H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Tretinoin liposome formulations and uses thereof to treat cancer8 Oct 2026US 2026/0306436 A1Highfield Biopharmaceuticals Corporation
- Use of retinoic acid receptor activator and composition thereof in regeneration and repair of mammals17 Sep 2026US 2026/0272871 A1Beijing Institute for Stem Cell and Regenerative Medicine
- Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer17 Sep 2026US 2026/0275342 A1Assistance Publique-Hopitaux de Paris
- Pvax14 nucleic acid formulated with nano-vehicle in combination with all-trans retinoic acid (atra) for activating immune pathways13 Aug 2026US 2026/0232777 A1Assistance Publique-Hopitaux de Paris
- Compositions comprising a retinoid and a processed oat ingredient6 Aug 2026US 2026/0224465 A1Kenvue Brands LLC
Most cited
By later US patents
- Anti-angiogenic compositions and methods of use968US 5,716,981 AAngiogenesis Technologies, Inc. · 1998
- Anti-angiogenic compositions and methods of use413US 5,886,026 AAngiotech Pharmaceuticals, Inc. · 1999
- Lineage-directed induction of human mesenchymal stem cell differentiation264US 5,736,396 ACase Western Reserve University · 1998
- Anti-angiogenic compositions and methods of use242US 6,544,544 B2Angiotech Pharmaceuticals, Inc. · 2003
- Lineage-directed induction of human mesenchymal stem cell differentiation212US 5,942,225 ACase Western Reserve University · 1999